Loading...
42 zinc COVID-19 controlled studies, 7 RCTs
https://c19zinc.com/meta.html
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Derwand 79%
0.21 [0.03-1.47]
death
1/141
13/377
CT2
Improvement, RR [CI] Treatment Control Derwand 82%
0.18 [0.07-0.54]
hosp.
4/141
58/377
CT2
Thomas (RCT) -44%
1.44 [0.36-5.71]
hosp.
5/58
3/50
Thomas (RCT) 12%
0.88 [0.67-1.16]
recov. time
58 (n)
50 (n)
Asimi 97%
0.03 [0.00-0.44]
ventilation
0/270
9/86
CT2
Asimi 99%
0.01 [0.00-0.16]
hosp.
0/270
24/86
CT2
Asimi 100%
0.00 [0.00-0.08]
severe case
0/270
51/86
CT2
Mayberry 53%
0.47 [0.33-0.65]
death
938 (n)
1,090 (n)
Mayberry 64%
0.36 [0.27-0.47]
ventilation
938 (n)
1,090 (n)
Mayberry 60%
0.40 [0.31-0.52]
ICU
938 (n)
1,090 (n)
Mayberry 58%
0.42 [0.33-0.54]
death/v/ICU
938 (n)
1,090 (n)
Mayberry 85%
0.15 [0.10-0.22]
progression
938 (n)
1,090 (n)
Carlucci 38%
0.62 [0.46-0.84]
death/HPC
54/411
119/521
Carlucci 18%
0.82 [0.54-1.25]
ventilation
29/411
62/521
Carlucci 23%
0.77 [0.53-1.10]
ICU
38/411
82/521
Krishnan 18%
0.82 [0.62-1.09]
death
31/58
61/94
Yao 34%
0.66 [0.41-1.07]
death
73/196
21/46
Frontera (PSM) 37%
0.63 [0.44-0.91]
death
121/1,006
424/2,467
CT2
Frontera (PSM) 24%
0.76 [0.60-0.96]
death
121/1,006
424/2,467
CT2
Abd-Elsalam (RCT) 1%
0.99 [0.30-3.31]
death
5/96
5/95
Abd-Elsalam (RCT) 34%
0.66 [0.19-2.26]
ventilation
4/96
6/95
Abd-Elsalam (RCT) 6%
0.94 [0.55-1.62]
no recov.
20/96
21/95
Abd-Elsalam (RCT) 4%
0.96 [0.86-1.08]
hosp. time
96 (n)
95 (n)
Rosenthal -16%
1.16 [1.05-1.28]
death
n/a
n/a
Darban (RCT) 33%
0.67 [0.14-3.17]
progression
2/10
3/10
ICU patients CT2
Darban (RCT) 6%
0.94 [0.84-1.06]
ICU
10 (n)
10 (n)
ICU patients CT2
Patel (DB RCT) 20%
0.80 [0.15-4.18]
death
2/15
3/18
Mulhem 46%
0.54 [0.43-0.68]
death
256/1,596
260/1,623
Gadhiya -41%
1.41 [0.69-2.57]
death
21/54
34/229
Al Sulaiman (ICU) 36%
0.64 [0.37-1.10]
death
23/82
32/82
ICU patients
Al Sulaiman (ICU) 48%
0.52 [0.29-0.92]
death
19/82
31/82
ICU patients
Al Sulaiman (ICU) -25%
1.25 [0.84-1.87]
ICU
82 (n)
82 (n)
ICU patients
Al Sulaiman (ICU) -6%
1.06 [0.85-1.33]
hosp. time
82 (n)
82 (n)
ICU patients
Elavarasi 65%
0.35 [0.24-0.56]
death
486 (n)
1,201 (n)
Assiri (ICU) -81%
1.81 [0.41-6.97]
death
10/60
4/58
ICU patients
Kaplan (RCT) -14%
1.14 [0.08-16.6]
ventilation
1/14
1/16
CT2
Kaplan (RCT) -14%
1.14 [0.08-16.6]
ICU
1/14
1/16
CT2
Kaplan (RCT) -14%
1.14 [0.08-16.6]
hosp.
1/14
1/16
CT2
Zangeneh (ICU) -21%
1.21 [0.51-2.90]
death
n/a
n/a
ICU patients
Alahmari 30%
0.70 [0.63-0.78]
hosp. time
130 (n)
847 (n)
Louca 1%
0.99 [0.93-1.06]
cases
Mahto 37%
0.63 [0.22-1.49]
IgG+
10/38
83/651
Holt 7%
0.93 [0.59-1.44]
cases
21/750
425/14,477
Abdulateef 13%
0.87 [0.38-1.97]
hosp.
7/111
23/317
Seet (CLUS. RCT) 50%
0.50 [0.34-0.75]
symp. case
33/634
64/619
OT1
Seet (CLUS. RCT) 27%
0.73 [0.41-1.05]
cases
300/634
433/619
OT1
Israel 100%
0.00 [0.00-0.89]
hosp.
case control
CT2
Bagheri 60%
0.40 [0.04-3.53]
progression
33 (n)
477 (n)
Bagheri 41%
0.59 [0.14-1.61]
hosp.
4/33
167/477
Gordon 68%
0.32 [0.01-7.87]
death
0/104
1/96
Gordon 85%
0.15 [0.02-0.58]
symp. case
2/104
9/96
Kumar 20%
0.80 [0.21-2.99]
death
6/75
3/30
Nimer -25%
1.25 [0.87-1.77]
hosp.
41/326
178/1,822
Nimer -13%
1.13 [0.81-1.56]
severe case
46/326
214/1,822
Shehab 47%
0.53 [0.19-1.47]
severe case
4/65
22/188
Stambouli (DB RCT) 68%
0.32 [0.03-2.95]
symp. case
1/59
3/56
Stambouli (DB RCT) 5%
0.95 [0.29-3.10]
cases
5/59
5/56
Stambouli (DB RCT) 21%
0.79 [0.73-0.84]
viral load
59 (n)
56 (n)
zinc COVID-19 outcomes c19zinc.com Jun 2022
1 OT: comparison with other treatment 2 CT: study uses combined treatment Favors zinc
Favors control
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation.
FLCCC and
WCH
provide treatment protocols.
Submit
